TSHA: Taysha Gene Therapies, Inc.
Performance
TSHA +14.10%
Watchlist
Select an item
Summary
TSHA at a glance
TSHA returned +14.10% over the past year and -22.21% a year over five years. Its worst drop in that year was -49.71%, smaller than 23% of stocks on Redstone, and its Sharpe ratio of 0.48 beats 49% of stocks on Redstone. It pays no dividends.
Current Drawdown
-37.39%
Rolling Volatility
83.13%
Actions
Metrics
Risk Indicators
Alpha17.20%
Beta1.78x
Sharpe0.48
Sortino0.75
Omega1.09
Calmar0.28
Martin1.64
Profile
About TSHA
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS.
- Sector
- Health Care
- Industry
- Biological Products, (no Diagnostic Substances)
- Market cap
- $1.4B
- Listed
- Sep 2020
- Employees
- 99
- Headquarters
- Dallas, TX
- Website
- tayshagtx.com
Comparisons